Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Evid Based Complement Alternat Med. 2013;2013:360149. doi: 10.1155/2013/360149. Epub 2013 Aug 19.
Objective. This trial aims to look for the protein biomarker of "toxin syndrome" of CHD patients. Methods. We have performed two trials in this paper. The first trial was a randomized controlled trial (RCT) of the plasma proteome in unstable angina (UA) patients by Maldi-Tof Mass. The second trial was a nested case-control study in 1503 stable CHD patients with one-year followup for acute cardiovascular events (ACEs). Results. In the RCT study, 12 protein spots were found to be the differential protein for the significant differences between the difference of before and after treatment in group A and group B; 2 of them (3207.37 Da and 4279.95 Da) was considered to be unique to "toxin syndrome" for being differential proteins of group B but not group A. These 2 spots were identified as Isoform 1 of Fibrinogen alpha chain precursor (FGA, 3207.37 Da) and Isoform 2 of inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4, 4279.95 Da), respectively. In the nested case-control study, the result of Western blot demonstrated that protein expression of ITIH4 in the group with followup ACEs was significantly lower than the matched group without followup ACEs (P = 0.027). Conclusion. ITIH4 might be a new potential biomarker of CHD "toxin syndrome" in TCM, indicating the potential role in early identifying high-risk CHD patients in stable period.
目的。本研究旨在寻找冠心病（CHD）患者“毒邪”证的蛋白生物标志物。方法。本文进行了两项试验。第一项试验是应用 MALDI-TOF-MS 对不稳定型心绞痛（UA）患者血浆蛋白质组进行的随机对照试验（RCT）。第二项试验是对 1503 例稳定型 CHD 患者进行的巢式病例对照研究，随访 1 年观察急性心血管事件（ACEs）。结果。在 RCT 研究中，发现 12 个蛋白斑点是 A 组和 B 组治疗前后差异的差异蛋白；其中 2 个（3207.37Da 和 4279.95Da）被认为是“毒邪”的独特差异蛋白，因为它们是 B 组而不是 A 组的差异蛋白。这两个斑点分别被鉴定为纤维蛋白原α链前体同工型 1（FGA，3207.37Da）和α-胰蛋白酶抑制剂重链 H4 同工型 2（ITIH4，4279.95Da）。在巢式病例对照研究中，Western blot 结果表明，随访 ACEs 组的 ITIH4 蛋白表达明显低于无随访 ACEs 的匹配组（P=0.027）。结论。ITIH4 可能是中医 CHD“毒邪”证的一个新的潜在生物标志物，表明其在稳定期早期识别高危 CHD 患者方面具有潜在作用。
